Over the years, extensive R&D efforts have enabled microbiome-based therapy / diagnostic developers to make significant strides, in terms of progressing proprietary product candidates into the clinic.
Roots Analysis has announced the addition of “Human Microbiome Market, 2021-2030” report to its list of offerings
The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:
• A detailed assessment of the current market landscape of microbiome therapeutics, providing information on drug / therapy developer(s).
• Elaborate profiles of key players (established after 2005) that are engaged in the development of microbiome therapeutics.
• A detailed review of the current market landscape of microbiome diagnostic tests, brief profiles of popular diagnostic developers and indicative list of screening and profiling test kits.
• A detailed assessment of the current market landscape of FMT therapies, a geographical clinical trial analysis and information on various stool banks.
• A detailed business portfolio analysis based on an attractiveness and competitiveness (AC) framework.
• An analysis of the varied microbiome-focused initiatives of big pharma players.
• An analysis of the start-ups / small-sized players engaged in the development of microbiome therapeutics and diagnostics.
• An assessment of the most commonly targeted therapeutic indications and details of microbiome-based drugs.
• An analysis of the investments made at various stages of development in start-ups / small-sized companies.
• An indicative list of contract manufacturers, in-house manufacturers and CROs that currently claim to have the necessary capabilities.
• An assessment of the emerging role of big data highlighting efforts focused on the development and implementation of various algorithms / tools to analyze data generated from in the microbiome research.
• An informative case study on the various other applications of microbiome products, such as agriculture, animal health, plant health, food products
Request for Customization: https://www.rootsanalysis.com/reports/281/request-sample.html
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Type of Therapy (Tx)
• Prescription Drug
• Prebiotics
• Probiotics
Type of Molecule (Tx)
• Small Molecules
• Biologics
Target Indication (Tx+Dx)
• Acne Vulgaris
• Atopic Dermatitis
• Clostridium difficile Infection
• Colorectal Cancer
• Crohn’s Disease
• Diabetes
• Irritable Bowel Syndrome
• Lactose Intolerance
• Lung Cancer
• Nonalcoholic steatohepatitis (NASH)
• Obesity
• Ulcerative colitis
Therapeutic Area (Tx+Dx)
• Autoimmune Disorders
• Dental Disorders
• Digestive and Gastrointestinal Disorders
• Dermatological Disorders
• Infectious Disease
• Metabolic Disorders
• Oncology
• Others
Key Geographical Regions (Tx+Dx)
• North America
• Europe
• Asia-Pacific and Rest of the World
Key companies covered in the report
• 4D Pharma
• Armata Pharmaceuticals
• Evelo Biosciences
• Rebiotix (Acquired by Ferring Pharmaceuticals)
• Seres Therapeutics
• Vedanta Biosciences
Request for PDF Sample Report:
https://www.rootsanalysis.com/reports/human-microbiome-market/request-customization.html